The invention provides a compound of Formula (I)
or a pharmaceutically acceptable salt of the compound, wherein R
1
, R
2
, R
3
and R
4
are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
[EN] ALKYL-AND DI-SUBSTITUTED AMIDO-BENZYL SULFONAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS SULFONAMIDES AMIDO-BENZYLIQUES SUBSTITUÉS PAR UN GROUPE ALKYLE ET DISUBSTITUÉS
申请人:GENENTECH INC
公开号:WO2013130943A1
公开(公告)日:2013-09-06
The present invention relates to certain alkyl- and di-substituted amido-benzyl sulfonamide compounds, pharmaceutical compositions comprising such compounds, and to methods of treatment of NAMPT-mediated disorders, such as diabetes, rheumatoid arthritis, atherosclerosis, sepsis, inflammation and cancers comprising administering a theraputically effective amount of the amido-benzyl sulfonamide compound to a subject in need of treatment.
The invention provides a compound of Formula (I)
or a pharmaceutically acceptable salt thereof; wherein
G is
R
1
, R
2
and R
3
are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
[EN] 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS D'ACIDE BENZOÏQUE À SUBSTITUTION 4-HÉTÉROARYLE EN TANT QU'INHIBITEURS DE RORGAMMAT ET LEURS UTILISATIONS
申请人:MERCK SHARP & DOHME
公开号:WO2014026327A1
公开(公告)日:2014-02-20
Provided are compounds according to Formula I or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
[EN] N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE N2-PYRAZOLOSPIROCÉTONE ACÉTYL-COA CARBOXYLASE
申请人:PFIZER
公开号:WO2011058473A1
公开(公告)日:2011-05-19
The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal.